

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

PROFIT ALERT

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (“**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2025 (“**FY2025**”), it is expected that:

- 1) the Group will record a revenue of approximately RMB7,700 million to RMB7,800 million for FY2025, representing an increase of approximately 16.0% to 17.6% as compared to the revenue of approximately RMB6,635 million for the year ended December 31, 2024 (“**FY2024**”).
- 2) the Group will record a profit attributable to equity shareholders of the Company of approximately RMB1,300 million to RMB1,400 million for FY2025, representing an increase of approximately 80.1% to 93.9% as compared to the restated profit attributable to equity shareholders of the Company of approximately RMB722 million for FY2024. The Group will record an adjusted profit attributable to equity shareholders of the Company¹ of approximately RMB1,250 million to RMB1,350 million for FY2025, representing an increase of approximately 24.1% to 34.1% as compared to the restated and adjusted profit attributable to equity shareholders of the Company of approximately RMB1,007 million for FY2024. The growth in the aforementioned items is primarily attributable to increases in revenue from innovative pharmaceutical business, income from out-licensing, and net gains in the fair value of the Group’s investment portfolio.

¹ To supplement the financial information presented in accordance with Hong Kong Financial Reporting Standards (“**HKFRS**”), the Group also uses adjusted profit attributable to equity shareholders of the Company as a non-HKFRS measure. Such measure is unaudited in nature and is not required by, or presented in accordance with, HKFRS.

The adjusted profit attributable to equity shareholders of the Company is defined by the Group as profit attributable to equity shareholders of the Company adjusted for the following items: (i) net realized and unrealized gain/(loss) on financial assets at fair value through profit or loss; (ii) net realized and unrealized gain on associates at fair value through profit or loss; (iii) interest expenses arising from redemption liability; and (iv) income tax effect related to the above items. The Group is of the view that the Group's management and investors may benefit from referring to such measure in assessing the financial performance of the Group's core businesses by eliminating the impacts of certain non-recurring, non-cash and/or non-operating items.

The Group prepared its consolidated financial information in respect of the acquisitions by applying the principles of merger accounting. Since the acquisition (the "Acquisition") of Xianwei (Hainan) Biotechnology Co., Ltd. ("Xianwei Hainan") was completed in October 2025, the comparative consolidated financial information of the Group for FY2024 has been restated as if the Acquisition had been completed at the beginning of the comparative period. Prior to restatement, the Group recorded a profit attributable to equity shareholders of the Company of approximately RMB733 million for FY2024, and an adjusted profit attributable to equity shareholders of the Company of approximately RMB1,018 million. Following the restatement, profit attributable to equity shareholders of the Company for FY2024 is expected to be approximately RMB722 million, and adjusted profit attributable to equity shareholders of the Company is expected to be approximately RMB1,007 million. The above restated financial information has not been audited or reviewed by the auditor. For more details on the Acquisition, please refer to the announcements of the Company dated August 26, 2025 and September 18, 2025.

The Company is still in the process of finalising the annual results of the Group for FY2025. The information contained in this announcement is based solely on the preliminary assessment of the Group's unaudited consolidated management accounts for FY2025, and is subject to finalisation and other potential adjustments, if any, and has not been reviewed or confirmed by the Group's auditors or the Audit Committee of the Board. Shareholders and potential investors of the Company should refer to the Group's annual results announcement for FY2025, which is expected to be published in late March 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, February 25, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.